Claims

1. Use of a DPP-4 inhibitor for preparing a pharmaceutical composition for use in wound healing in diabetic patients, wherein said DPP-4 inhibitor is
1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(*R*)-amino-piperidin-1-yl)-xanthine, or
1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((*R*)-3-amino-piperidin-1-yl)-xanthine,
or a pharmaceutically acceptable salt thereof.

2. The use according to claim 1, ~~wherein the pharmaceutical composition is for wound healing,~~ wherein said DPP-4 inhibitor is 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(*R*)-amino-piperidin-1-yl)-xanthine.

3. The use according to any one of the claims 1 to 2, wherein the pharmaceutical composition is for wound healing in diabetic patients, wherein said DPP-4 inhibitor is administered orally.

4. The use according to any one of the claims 1 to 2, wherein the pharmaceutical composition is for wound healing in diabetic patients, wherein said DPP-4 inhibitor is administered topically.

~~5. The use according to any one of the claims 1 to 4, wherein the pharmaceutical composition is for improving wound epithelialization.~~

~~6. The use according to any one of the claims 1 to 5, wherein the pharmaceutical composition is for promoting neo-epithelialization.~~

~~7. The use according to any one of the claims 1 to 6, wherein the pharmaceutical composition is for promoting tissue regeneration.~~

~~8. The use according to any one of the claims 1 to 7, wherein the pharmaceutical composition is for diminishing wound size.~~

~~9. The use according to any one of the claims 1 to 8, wherein the pharmaceutical composition is for reducing destructive wound inflammation.~~

~~10. The use according to claim 9, wherein the pharmaceutical composition is for reducing the number of polymorphonuclear neutrophils (PMN).~~

~~11. The use according to any one of the claims 5 to 10, wherein the pharmaceutical composition is used for diabetes-associated wounds.~~

~~12. The use according to any one of the claims 1 to 11, wherein the pharmaceutical composition is for treating and/or preventing wound healing deficit or impairments in the wound healing process.~~

~~13. The use according to any one of claims 1 to 12, wherein the pharmaceutical composition is used in diabetic patients.~~

~~14~~5. Use of a ~~a~~ tablet for oral use or a topical preparation for preparing a medicament for use in wound healing in diabetic patients, said tablet or topical preparation comprising 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(*R*)-amino-piperidin-1-yl)-xanthine.

~~15~~6. A topical preparation comprising 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(*R*)-amino-piperidin-1-yl)-xanthine, with suitable carrier materials for topical preparations.

~~16~~7. The topical preparation according to claim ~~15~~6, which is an ointment.

~~17~~8. Use of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(*R*)-amino-piperidin-1-yl)-xanthine for preparing a medicament for topical use.

~~18~~9. Use of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(*R*)-amino-piperidin-1-yl)-xanthine, for the manufacture of a pharmaceutical composition for wound healing in diabetic patients.

~~19~~10. Use according to claim ~~18~~9, wherein the pharmaceutical composition can be administered orally.

~~20~~11. Use according to claim ~~18~~9, wherein the pharmaceutical composition can be administered topically.

~~21~~12. The use according to any one of the claims 1 to ~~13~~4, wherein 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(*R*)-amino-piperidin-1-yl)-xanthine in the pharmaceutical composition is used in combination with one or more other therapeutically active agents for separate, sequential, simultaneous, concurrent or chronologically staggered use in wound healing.

~~22~~13. The use according to any one of the claims 1 to ~~13~~4, wherein 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(*R*)-amino-piperidin-1-yl)-xanthine in the pharmaceutical composition is used in combination with one or more other therapeutically active agents selected from metformin, pioglitazone and telmisartan, for separate, sequential, simultaneous, concurrent or chronologically staggered use in wound healing in diabetic patients.

~~23. The use according to any one of the claims 1 to 13, 21 or 22, wherein said DPP-4 inhibitor exerts direct favourable effects on the wound repairing process in a type 2 diabetic subject.~~

~~24. The use according to claim 23, wherein said direct favourable effect is an extraglycemic effect.~~

~~25. The use according to any one of the claims 1 to 13 or 21 to 24, wherein said DPP-4 inhibitor is suitable for providing additional therapeutic benefits to patients with or at risk of skin diseases, wounds and/or wound healing disturbances or impairments beyond improving glycemic control.~~

14. Use of a DPP-4 inhibitor for preparing a pharmaceutical composition for treating skin diseases and/or wounds in diabetic patients, wherein said DPP-4 inhibitor is
1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(*R*)-amino-piperidin-1-yl)-xanthine, or
1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((*R*)-3-amino-piperidin-1-yl)-xanthine,
or a pharmaceutically acceptable salt thereof;
wherein the pharmaceutical composition is administered topically.

15. The use according to claim 14, wherein a chronic wound, sore, ulcer or diabetic foot is treated.